Agnes Shanley

As politicians focus on drug cost reduction, biopharmaceutical companies in the US are moving to states with lower taxes, and relocating some facilities that had been offshore.

Vein-to-vein programs are focusing on data access and traceability.

While the US public and law makers push for price controls, pharma’s venture capitalists have other ideas for balancing innovation and affordability.

Focusing on symptoms instead of root causes locks teams into a corrective, rather than preventive, mindset.